Ultragenyx Pharmaceutical
RARE
#5062
Rank
โ‚น163.71 B
Marketcap
โ‚น1,606
Share price
-2.88%
Change (1 day)
-43.02%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -โ‚น41.77 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are โ‚น0.73 Billion. In 2025 the company made an earning of -โ‚น47.5 Billion a decrease over its 2024 earnings that were of -โ‚น47.07 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -โ‚น41.77 Billion-12.07%
2025 -โ‚น47.5 Billion0.93%
2024 -โ‚น47.07 Billion-6.99%
2023 -โ‚น50.61 Billion-17.65%
2022 -โ‚น61.45 Billion55.52%
2021 -โ‚น39.51 Billion178.53%
2020 -โ‚น14.19 Billion-59.64%
2019 -โ‚น35.15 Billion1.46%
2018 -โ‚น34.65 Billion12.9%
2017 -โ‚น30.69 Billion32.63%
2016 -โ‚น23.14 Billion67.87%
2015 -โ‚น13.79 Billion160.2%
2014 -โ‚น5.3 Billion66.64%
2013 -โ‚น3.18 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-โ‚น5.71 Billion-86.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
โ‚น7.40 B-117.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น17.81 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚น4.07 B-109.76%๐Ÿ‡บ๐Ÿ‡ธ USA